Comparative Pharmacology
Head-to-head clinical analysis: DIACOMIT versus FYCOMPA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIACOMIT versus FYCOMPA.
DIACOMIT vs FYCOMPA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Stiripentol is an anticonvulsant that potentiates GABAergic neurotransmission by acting as a positive allosteric modulator of GABA-A receptors and inhibiting GABA transaminase. It also inhibits CYP2C19 and other cytochrome P450 enzymes, thereby increasing plasma concentrations of concomitant antiepileptic drugs like clobazam.
Non-competitive AMPA receptor antagonist; inhibits glutamate-mediated excitatory neurotransmission by selectively targeting AMPA receptors.
10 mg/kg/day orally in two divided doses; increase weekly by 10 mg/kg/day to 70 mg/kg/day or 3 g/day, whichever is lower.
Initial: 2 mg orally once daily; titrate weekly by 2 mg increments to maintenance dose of 4-12 mg once daily depending on seizure type and tolerability; maximum 12 mg once daily.
None Documented
None Documented
Terminal elimination half-life: 13-20 hours; in severe renal impairment (CrCl <30 mL/min), half-life prolonged to 40-60 hours. Requires dose adjustment.
Terminal elimination half-life is approximately 105 hours (range 80-120 hours) in patients with epilepsy; supports once-daily dosing.
Primarily renal excretion: 50% as unchanged drug, 30% as glucuronide conjugate, 20% via fecal/biliary routes.
Renal: approximately 30% as unchanged drug; fecal: approximately 70% (mostly as metabolites, minimal unchanged).
Category C
Category C
Anticonvulsant
Anticonvulsant